BioInsights - When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

Cell & Gene Therapy Insights 2021; 7(7), 857–869

10.18609/cgti.2021.117

Published: 14 October 2021
Innovator Insight
Kaman Kim, Carlos Yuraszeck, Joseph O’Connor

To allow greater flexibility and better targeting of CAR T cell therapies, Astellas developed convertibleCAR™ T cells, which kill antigen-expressing target cells only in the presence of an activating bispecific adapter. Here, we will discuss the clinical manufacturing of autologous convertibleCAR T cells, with a special focus on automation of the process using the Lonza Cocoon® Platform.